Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial

In VERTIS CV, baseline use of diuretics, particularly loop diuretics, identified a subgroup that demonstrated greater benefit with ertugliflozin on first HHF/CV death and HHF outcomes, with no modification of treatment effect observed with baseline use of RAAS inhibitors or MRAs. There was no evidence of treatment effect on the kidney composite outcomes by baseline use of RAAS inhibitors, diuretics, loop diuretics, or MRAs.

Authors

Institutions

Publication Details

Journal
Kidney Diseases
Published
2025-02-04
DOI
https://doi.org/10.1159/000543162
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial

Christopher P. Cannon, Ira Gantz, David Z.I. Cherney, Samuel E. Dagogo-Jack et al.
Kidney Diseases
Diabetes Treatment and Management
article

Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial

Christopher P. Cannon, Ira Gantz, David Z.I. Cherney, Samuel E. Dagogo-Jack, Robert Frederich, Urszula Masiukiewicz, Richard E. Pratley, Nilo B. Cater, Francesco Cosentino, Annpey Pong, James P. Mancuso
article en

Abstract

In VERTIS CV, baseline use of diuretics, particularly loop diuretics, identified a subgroup that demonstrated greater benefit with ertugliflozin on first HHF/CV death and HHF outcomes, with no modification of treatment effect observed with baseline use of RAAS inhibitors or MRAs. There was no evidence of treatment effect on the kidney composite outcomes by baseline use of RAAS inhibitors, diuretics, loop diuretics, or MRAs.

Kidney DiseasesVol. 11(1)
Brigham and Women's Hospital (US), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Karolinska University Hospital (SE), Harvard University (US), University of Tennessee Health Science Center (US), Pfizer (United States) (US), University of Toronto (CA), Karolinska Institutet (SE), Translational Research Institute for Metabolism and Diabetes (US)
American Diabetes Association, Pfizer, European Foundation for the Study of Diabetes, European Association for the Study of Diabetes
Openalex Percentile: Top 97%
Diabetes Treatment and Management
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.